Key result
IV P-CD34 promotes endogenous CD34 stem cell accumulation in injured hearts following murine acute MI.
Why the study?
Current stem cell therapies for ischemic heart disease are limited by the low retention and poor integration of injected cells in injured tissue.
Does intravenous administration of CD34 antibody-linked platelets improve heart repair in a mouse model of acute myocardial infarction?
Does intravenous administration of CD34 antibody-linked platelets improve heart repair in a mouse model of acute myocardial infarction?
Engineering platelets with CD34 antibodies represents a novel technology to direct endogenous stem cells to injured myocardium for heart repair.
May enable targeted stem cell recruitment post-MI; hypothesis-generating for repair efficacy, requires functional validation in larger models.
Stem cell therapies have shown promise in treating acute and chronic ischemic heart disease. However, current therapies are limited by the low retention and poor integration of injected cells in the injured tissue. Taking advantage of the natural infarct-homing ability of platelets, we engineered CD34 antibody-linked platelets (P-CD34) to capture circulating CD34-positive endogenous stem cells and direct them to the injured heart. In vitro, P-CD34 could bind to damaged aortas and capture endogenous stem cells in whole blood. In a mouse model of acute myocardial infarction, P-CD34 accumulated in the injured heart after intravenous administration, leading to a concentration of endogenous CD34 stem cells in the injured heart for effective heart repair. This represents a new technology for endogenous stem cell therapy.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2019) studied acute myocardial infarction. CD34 antibody-linked platelets (P-CD34) was evaluated on accumulation in the injured heart and concentration of endogenous CD34 stem cells. Intravenous administration of CD34 antibody-linked platelets (P-CD34) in a mouse model of acute myocardial infarction led to accumulation of endogenous CD34 stem cells in the injured heart.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: